Compare Crispr Therapeutics AG (CRSP) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Advanced Drainage Systems Inc — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Advanced Drainage Systems Inc trades at $147.16 (market cap $11.57B). The key difference: Advanced Drainage Systems Inc is far larger — about 2.3× Crispr Therapeutics AG's market cap, and Advanced Drainage Systems Inc pays a 0.53% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WMS | |
|---|---|---|
Market Cap | $4.97B | $11.57B |
Sector | Health | Industrials |
52-Week High | $76.78 | $175.38 |
52-Week Low | $44.34 | $110.89 |
Enterprise Value | $3.32B | $13.14B |
Dividend Yield | — | 0.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
WMS trades at $147.62, down 1.89% on the day, with a bullish technical signal and strong fundamentals including a 24.02% ROE and consistent earnings beats. Recent news includes a dividend increase and investor day, while cash flow dipped in 2025 but is projected to recover. The stock shows robust profitability with a 13.98% net margin and trades below the consensus price target of $184.43.
Outlook is positive with analyst support and operational strength, but risks include a high P/E of 27.09 and mixed sentiment from recent Strong Sell ratings. Upside potential exists if earnings momentum continues, though investors should monitor debt levels and competitive pressures in the water management sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
